Investment bank: Bavarian Nordic's RSV data reduces risk associated with important asset

Wednesday’s positive RSV vaccine candidate results from Bavarian Nordic could pave the way for positive dialog with possible partners before a phase III trial study begins, reads a comment from US-based investment bank Jefferies.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
BY RITZAU FINANS, TRANSLATED BY DANIEL INGEMANN KROIER PEDERSEN

Bavarian Nordic recently publicized positive results from a data study of its RSV vaccine candidate, MVA-BN RSV, which has shown a very good efficacy rate in its phase II study compared to the placebo.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading